Comparison Of Adverse Reactions And Short-term Clinical Efficacy Of Two Platinum Combined With Paclitaxel In Ovarian Cancer Chemotherapy

Objective :To observe,compare and analyze the adverse reactions and short-term clinical efficacy of lobaplatin or carboplatin combined with paclitaxel in ovarian cancer chemotherapy.Methods :A retrospective study was conducted on 60 patients with ovarian cancer who received postoperative chemotherapy from March 2016 to January 2018 in the Department of gynecology or oncology of our hospital.The patients were divided into two groups:lobaplatin group and carboplatin group.Among them,30 patients received lobaplatin combined with paclitaxel for 3-6 cycles of chemotherapy,and another 30 patients received carboplatin combined with paclitaxel for 3-6 cycles of chemotherapy.The patients with advanced ovarian cancer(FIGO stage III and IV)in the lobaplatin group and the carboplatin group were selected to observe the short-term clinical efficacy.They were corresponding to the lobaplatin therapy group and the carboplatin therapy group respectively.There were 22 cases in the lobaplatin therapy group and 19 cases in the carboplatin therapy group.By referring to WHO(World Health Organization)criteria for toxicity and side effects of anticancer drugs and evaluation criteria for reaction to solid tumor therapy(RECIST),serum tumor markers CA125 and HE4 were recorded before and after chemotherapy,the incidence of toxicity and side effects after chemotherapy in patients with lobaplatin and carboplatin were compared and analyzed,and the short-term clinical efficacy and changes of serumtumor markers in patients with lobaplatin therapy group and carboplatin therapy group were compared and analyzed.Results:1.There was no significant difference between the adverse reaction and short-term clinical efficacy of ovarian cancer chemotherapy and age,pathological type,FIGO stage and physical performance score(P > 0.05).2.Comparison of adverse reactions between the two groups,the common adverse reactions such as bone marrow depression,alopecia,impairment of liver and kidney function,nausea and vomiting in the lobaplatin group,The common adverse reactions in carboplatin group were bone marrow depression,alopecia,impairment of liver and kidney function,nausea and vomiting.Diarrhea,fever and neurosensory abnormalities were lower in both groups.However,compared with the two groups,the incidence of bone marrow depression in the lobaplatin group was significantly lower than that in the carboplatin group,especially leukopenia and thrombocytopenia.There was significant difference between the two groups(P < 0.05).There was no significant difference in other adverse reactions between the two groups(P > 0.05).3.Comparison of short-term clinical efficacy between the two groups,the remission rate of lobaplatin therapy group was 77.27% and the total effective rate was 81.82%.The remission rate of carboplatin therapy group was 73.68% and the total effective rate was78.95%.There was no significant difference between the two groups(P > 0.05).After chemotherapy,serum CA125 and HE4 levels in one PD patient were significantly higher than those before chemotherapy in the lobaplatin therapy group,while serum CA125 and HE4 levels in one CR patient were slightly higher than those before chemotherapy.The serum CA125 and HE4 of one PD patient in the carboplatin therapy group were significantly higher than those before chemotherapy,and HE4 of three CR patients was slightly higher than thosebefore chemotherapy.The serum tumor markers CA125 and HE4 in the other patients were significantly lower than those before chemotherapy.There was no significant difference in the decline levels of CA125 and HE4 between the two groups(P > 0.05).According to telephone and/or outpatient follow-up after chemotherapy,the 1-year survival rates of patients in the lobaplatin and carboplatin therapy groups were 100%.Conclusion:1.Lobaplatin combined with paclitaxel has a lower incidence of bone marrow suppression than carboplatin,but there is no significant difference in liver and kidney function damage,gastrointestinal reaction,fever,alopecia and neurosensory abnormalities.2.Lobaplatin or carboplatin combined with paclitaxel are effective chemotherapy regimens for ovarian cancer,and their short-term clinical efficacy is similar.3.Lobaplatin is a low toxicity and effective new anti-cancer drug.The use of chemotherapy in ovarian cancer is relatively safer and easier to accept.